Analyser av Hansa Biopharma

Hansa Biopharma: Positiva data från PAES-studien - InvesteraMera

InvesteraMera lämnar en kort kommentar på de övergripande data som presenterades från den europeiska PAES-studien under onsdagen.

InvesteraMera • 28 maj 07:11

Hansa Biopharma: PAES Data Clears the Path for Full EU Approval - Redeye

Hansa Biopharma has announced positive topline results from its European 20-HMedIdeS-19 Post Authorisation Efficacy Study (PAES) for Idefiri...

Redeye • 27 maj 10:08

Hansa Biopharma: Kommentar på licensavtal - InvesteraMera

InvesteraMera ger en kommentar på licensavtalet för Idefirix mellan Hansa Biopharma och SERB Pharmaceuticals.

InvesteraMera • 20 maj 09:48

Hansa Biopharma: Lower WACC Results in Reiterated Base Case - Redeye

Redeye returns with a comment after the conference call on the EUR115m licensing deal yesterday.

Redeye • 20 maj 07:27

Hansa Biopharma: 115m EUR Licensing Deal in Europe - Redeye

Redeye comments on the licensing deal with SERB Pharmaceuticals for IDEFIRIX in Europe and MENA.

Redeye • 19 maj 09:38

Hansa Biopharma: Kommentar på Hansa Biopharma Q1 - InvesteraMera

InvesteraMera ger en kommentar på Q1-rapporten från Hansa Biopharma.

InvesteraMera • 27 apr 08:50

Hansa Biopharma (Q1 update): Soft Quarter Creates Opportunity - Redeye

Redeye comments on Hansa Biopharma's Q4 report. Revenues were SEK35m (SEK66m).

Redeye • 24 apr 07:23

Hansa Biopharma (Q1 Initial take): Soft Q1, as Expected - Redeye

Redeye provides its first take on Hansa Biopharma's Q1 report.

Redeye • 23 apr 08:56

Hansa Biopharma: Djupanalys - InvesteraMera

InvesteraMera inleder uppdragsbevakning av Hansa Biopharma, ett bioteknikbolag vars läkemedel imlifidase snabbt och effektivt klyver kroppen...

Research feed • 15 apr 09:27

Hansa Biopharma: Convertible Note De-Risks the Case - Redeye

Redeye comments on the USD30m convertible note issued by Hansa Biopharma to Athyrium Capital Management last week.

Redeye • 24 mar 08:13

Hansa Biopharma: PDUFA Action Date December 19 - Redeye

Yesterday evening, Hansa Biopharma announced a PDUFA date of 19 December, indicating a standard rather than a priority review.

Redeye • 05 mar 08:47

Hansa Biopharma (Q4 update): Strong Quarter in Europe - Redeye

Redeye comments on Hansa Biopharma's Q4 report. Revenues were SEK76m in the quarter, a strong beat of our estimate.

Redeye • 12 feb 11:28

Hansa Biopharma (Q4 initial take): Strong European Sales Beats Forecast - Redeye

Redeye comments on Hansa Biopharma's Q4 report. Revenues were SEK76m in the quarter, a strong beat of our estimate.

Redeye • 11 feb 10:17

Hansa Biopharma: Negative anti-GBM Phase III Readout - Redeye

Redeye comments on the topline data from the phase III study of imlifidase in anti-GBM disease.

Redeye • 17 dec 2025 08:50

Hansa Biopharma: Notes on KOL Comments on ConfideS - Redeye

Redeye comments on the KOL event 12 November. The KOL's opinions strenghten our conviction in a successful US launch of imlifidase.

Redeye • 13 nov 2025 07:16

Hansa Biopharma (Q3 Update): Europe Below Expectations, but the US Will Drive Value - Redeye

Redeye comments on Hansa Biopharma's Q3 report. Product sales declined sequentially in Europe.

Redeye • 03 nov 2025 11:34

Hansa Biopharma (Q3 Initial take): Sequential Sales Decline but Clinical Success - Redeye

Redeye provides its initial take on Hansa Biopharma’s Q3 report.

Redeye • 30 okt 2025 08:30

Hans Biopharma: Positive Gene Therapy Data - Redeye

Redeye believes gene therapy is an interesting area for imlifidase.

Redeye • 10 okt 2025 11:07

Hansa Biopharma: Directed Share Issue of USD71m - Redeye

Redeye is optimistic after Hansa’s directed share issue tonight, which was expanded from USD60m to USD71m due to strong demand.

Redeye • 02 okt 2025 09:38

Hansa Biopharma: Imlifidase confirms strong Kidney outcome in the US study - Redeye

The preliminary US ConfIdes results confirms that Kidney transplants supported by Imlifidase preserves a high eGFR level.

Redeye • 25 sep 2025 07:26

Hansa Biopharma: Supportive top-line clinical results in sequential gene therapy combination - Redeye

The combination of ELEVIDYS from Sarepta and Imlifidase records early supportive top-line data for patients resistant to ELEVIDYS when treat...

Redeye • 04 aug 2025 10:22

Hansa Biopharma: Sales support, easing funding pressure as the strategic review continues - Redeye

Hansa is better positioned to support its main value drivers, engage in strategic priorities, and potentially extend the number of commercia...

Redeye • 17 jul 2025 09:39

Hansa Biopharma: Easing the financial pressure and the ability to pursue substantial growth opportunities - Redeye

Hansa Biopharma intends to carry out a 10m Directed share issue executed by an accelerated book building.

Redeye • 19 jun 2025 07:18

Hansa Biopharma: Decides to cut projected annual operational cost by SEK 40-50m - Redeye

Hansa Biopharma plans to restructure the organisation to optimise resource allocation and improve operational efficiency.

Redeye • 27 maj 2025 08:59

Hansa Biopharma: The new CEO expands the team - Redeye

The new CEO, Renee Aguiar-Lucander, has signed Maria Törnsén as COO and president of the US operations.

Redeye • 13 maj 2025 12:04

Hansa Biopharma update: The European launch regains momentum - Redeye

With the increased number of active centers, the complete enrolment of the European PAES study, and the record level of IDEFIRIX product sal...

Redeye • 29 apr 2025 14:30

Hansa Biopharma Q1: The European launch regains momentum - Redeye

Following low volumes in the previous Q4, Hansa’s Q1 is well above the rolling 12m average, and the product sales of SEK 65.

Redeye • 24 apr 2025 13:19

Hansa Biopharma: Ends 2024 on a soft note - Redeye

After a period of steady increase in both European Idefirix sales and patient usage, Hansa records a softer Q4, with sales limited to SEK 25...

Redeye • 10 feb 2025 11:53

Hansa Biopharma: Ends 2024 on a softer note - Redeye

After a period of steady increase in both European Idefirix sales and patient usage, Hansa records a softer Q4, with sales limited to SEK 25...

Redeye • 06 feb 2025 11:51

Hansa Biopharma GBS has advanced to become another value driver - Redeye

Imflifidase shows robust efficacy results in phase 2 among patients with severe GBS.

Redeye • 20 dec 2024 13:19

Hansa Biopharma: Continuing progress with gene therapy partners - Redeye

Hansa’s partner Genethon initiates a phase 2 study based on Imlifidase as a pre-treatment ahead of GNT-0003 in the ultra-rare indication of ...

Redeye • 04 dec 2024 09:32

Hansa Biopharma: Improved use of IDEFIRIX - Redeye

Hansa delivers a healthy increase in patients using IDEFIRIX.

Redeye • 18 okt 2024 09:01

Hansa Biopharma: Improved use of IDEFIRIX - Redeye

Hansa delivers a healthy increase in patients using IDEFIRIX.

Redeye • 17 okt 2024 09:20

Hansa Biopharma: NiceR is in a good position to expand the future market - Redeye

Almost a year after announcing positive high level results Hansa Biopharma provides additional supporting results from the Phase 1 study as ...

Redeye • 08 okt 2024 08:50

Hansa Biopharma: Continuous progress is temporarily blurred by true-up - Redeye

Hansa’s launch progress continues in Q2. The net sales include provisions reflecting an extended period of “true-up” relating to the effect ...

Redeye • 22 jul 2024 08:16

Hansa Q2: Continuous progress is temporarily blurred by true-up - Redeye

Hansa’s Q2 sales confirm a period of continuing progress.

Redeye • 18 jul 2024 09:40

Hansa Biopharma Q1: Improved European launch support - Redeye

Redeye updates its outlook on Hansa Biopharma, anticipating improved launch support during 2024 and pipeline progress over the next 12 month...

Redeye • 19 apr 2024 08:49

Hansa Biopharma Q1: Improved outlook - Redeye

Hansa’s Q1 result includes a positive outlook in 2024 supported by additional countries and the Eurotransplant program.

Redeye • 18 apr 2024 09:25

Hansa Biopharma: Secures growth capital supported by two solid quarters - Redeye

Hansa Biopharma has announced a consecutive quarter with robust sales and the company has secured additional SEK 372m of growth capital on g...

Redeye • 12 apr 2024 14:02

Hansa Biopharma: Imlifidase continues to deliver improved sales in early 2024 - Redeye

Hansa’s preliminary Q1 result suggests that Idefirix records European product sales of SEK 48 (43m in Q4) in Q1.

Redeye • 02 apr 2024 14:26

Hansa Biopharma: Improved sales prospects - Redeye

Redeye updates its outlook on Hansa Biopharma, anticipating improved launch support during 2024 and supporting pipeline progress over the ne...

Redeye • 05 feb 2024 09:48

Hansa Biopharma: Confirms a record quarter Idefirix - Redeye

Hansa’s actual outcome after the trading outcome confirms that Idefirix records European product sales of SEK 43m in Q4.

Redeye • 02 feb 2024 09:19

Hansa Biopharma: Imlifidase records a very healthy improvement during Q4 after a quarter with low activity - Redeye

Hansa delivers a positive surprise in Q4 as Idefirix records European product sales of SEK 43m in Q4, which compares with our expected SEK 2...

Redeye • 08 jan 2024 09:02

Hansa Biopharma: AMR study with a convincing primary endpoint result - Redeye

Imlifidase shows a superior ability reducing donor-specific antibodies (DSAs) in the phase 2 study involving 30 AMR patients compared with P...

Redeye • 15 dec 2023 13:12

Hansa: Positive initial GBS results and additional savings - Redeye

Hansa adds positive 6m initial safety and early signs of efficacy in from the phase 2 GBS trial.

Redeye • 07 dec 2023 09:17

Hansa Biopharma: Ögonen på pipeline i Q4 - Penser

Dålig leverans i Q3 Hansas rapport för det tredje kvartalet innebar en svagare försäljning, men en lägre rörelseförlust än förväntat.

Penser • 27 okt 2023 11:43

Hansa Biopharma Q3 update: Slow progress ahead of 2024 - Redeye

Redeye updates its outlook on Hansa Biopharma, anticipating gradual launch support during 2023 and supporting pipeline progress over the nex...

Redeye • 27 okt 2023 08:48

Hansa Biopharma: 5-year efficacy support for Imlifidase/Idefirix ahead of the AMR publication - Redeye

Hansa publishes strong results 5-year after a kidney transplant supported by Idefirix.

Redeye • 17 okt 2023 09:17

Hansa Biopharma: Tuffa tider - Penser

Försening i ConfIdes-studien Hansa kom under förra veckan med en bolagsuppdatering.

Penser • 16 okt 2023 11:10

Hansa Biopharma: Soft Idefirix sales in Europe and a slipping US timetable for the US launch - Redeye

Hansa has provided a clinical update and top-line results ahead of the Q3 results.

Redeye • 12 okt 2023 14:13

Hansa Biopharma: Mot ett händelserikt H2 - Penser

Försäljning som förväntat – EBIT lägre Hansa levererade under torsdagen en stabil Q2-rapport.

Penser • 21 jul 2023 11:35

Hansa: Progress at a higher cost - Redeye

Redeye updates its outlook on Hansa Biopharma anticipating gradual launch support during 2023 and supporting pipeline progress over the next...

Redeye • 21 jul 2023 08:20

Hansa Biopharma: Improved sales and pipeline activity at a higher cost - Redeye

Hansa delivers positive sales in Q2 and SEK 30m of product sales is the highest lever within a year.

Redeye • 20 jul 2023 08:43

Hansa Biopharma; Expanding future potential support from gene therapy collaboration - Redeye

Hansa has established a research and development collaboration with French Genenthon based on the candidate GNT-0003 which has recently ente...

Redeye • 28 apr 2023 11:22

Hansa Biopharma: Ljusning i horisonten - Penser

Q1 - något svagare finansiellt Hansa levererade under torsdagen sin Q1-rapport.

Penser • 21 apr 2023 11:12

Hansa Biopharma: Update after Q1 with our revised outlook - Redeye

Redeye updates its outlook on Hansa Biopharma, anticipating gradual launch support during 2023 and supporting pipeline progress over the nex...

Redeye • 21 apr 2023 08:49

Hansa: Development progress but slow sales - Redeye

Hansa’s Q1 is soft in terms of product sales. We expect 2023 recurring sales contributions to be squewed towards the second half.

Redeye • 20 apr 2023 09:26

Hansa Biopharma: Preview Q1-rapport - Penser

Justerar kvartalsestimat Vi har gått igenom våra estimat och valt att göra vissa justeringar på kvartalsnivå för 2023.

Penser • 17 apr 2023 11:14

Hansa Biopharma: Update ahead of 2023 – Gradual progress ahead - Redeye

Redeye updates its outlook on Hansa Biopharma, anticipating gradual launch support during 2023 and supporting pipeline progress over the nex...

Redeye • 10 feb 2023 10:00

Hansa Biopharma: Ett år med många triggers väntar - Penser

Q4 rapport Hansas rapport för det fjärde kvartalet var i stora drag i linje med våra förväntningar.

Penser • 03 feb 2023 11:15

Hansa Biopharma: Our initial Q4 take - Redeye

Hansa's Q4 is slightly below our and the market's sales expectations and slightly better in terms of OPEX and operating cash flow.

Redeye • 02 feb 2023 09:09

Hansa Biopharma: Adding growth capital ahead of the US launch - Redeye

Hansa has done a directed share issue adding SEK 420m in growth capital mainly supporting the US launch of Idifirix and to progress with an ...

Redeye • 13 dec 2022 11:50

Hansa Biopharma: Studiedata stundar - Penser

Rapportkommentar Q3 Hansa släppte en Q3-rapport över våra förväntningar.

Penser • 27 okt 2022 11:28

Hansa Biopharma: Q3 Launch and Genetic exploratory progress - Redeye

Idefirix accounts a relatively solid Q3 despite holiday interruptions.

Redeye • 20 okt 2022 09:13

Hansa Biopharma: Inför Q3-rapport - Penser

Kvartalsestimat I denna analysuppdatering väljer vi att för första gången publicera estimat på kvartalsbasis.

Penser • 07 okt 2022 11:10

Hansa Biopharma: Snygg finansieringslösning - Penser

Försäljning i linje med våra förväntningar Hansa presenterade under gårdagen sin rapport för det andra kvartalet.

Penser • 20 jul 2022 11:11

Hansa Biopharma Q2: Idefirix sales progress and secured funding to end 2024 - Redeye

Hansa Biopharma (Hansa) delivers another quarter with improved Idefirix European sales.

Redeye • 19 jul 2022 12:40

Hansa Biopharma: Activates the European confirmation study for Idefirix - Redeye

The news is welcome as the 50-patient European PAES study expands the European reference clinics and the study is also a requirement to adva...

Redeye • 11 jul 2022 11:49

Hansa Biopharma: Stark försäljning i kvartalet - Penser

Q1-rapporten Hansa släppte igår sin rapport för det första kvartalet 2022.

Penser • 22 apr 2022 11:10

Hansa Biopharma Q1: The early European launch steps up a gear - Redeye

Idefirix has secured pricing and reimbursement in Sweden, the Netherlands and Germany, and on an individual hospital basis in Finland and Gr...

Redeye • 21 apr 2022 09:44